Silexion Therapeutics Receives Nasdaq Delisting Notice Over Equity Shortfall

What happened

Silexion Therapeutics Corp (Nasdaq: SLXN), a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapies for cancer, disclosed in an SEC filing on August 21, 2026, that it received a delisting notice from Nasdaq on August 18, 2026.

The notice stems from the company's failure to comply with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in shareholders' equity for continued listing on the Nasdaq Capital Market. The company's quarterly report for the period ended June 30, 2026 reported shareholders' equity of just $44,000.

Silexion said it intends to request an appeal before a Nasdaq Hearings Panel by August 25, 2026. The company stated it will present evidence of steps it has taken and will continue to take to restore compliance, but noted there is no assurance the appeal will succeed.

If the appeal is unsuccessful, trading in the company's ordinary shares and warrants would be suspended and a Form 25-NSE would be filed to remove the securities from Nasdaq.

Background

Silexion is a Cayman Islands exempted company headquartered in Ramat-Gan, Israel. It develops RNAi-based therapeutics targeting solid tumors, including pancreatic cancer.

The company is already under a Mandatory Hearings Panel Monitor, imposed after a September 23, 2025 Panel decision. Under Nasdaq Listing Rule 5815(d)(4)(B), the Listing Qualifications Department cannot grant additional time to regain compliance during the one-year monitoring period, which led to the delisting notice.

The company noted that while it had believed it restored compliance as of the August 14, 2026 filing date of its Form 10-Q, based on pro forma equity as of June 30, 2026, subsequent net losses have left it below the threshold.

What this means

A Form 8-K is a current report companies must file with the SEC to announce major events. Item 3.01 of the form specifically covers delisting notices or failures to meet listing standards.

Shareholders' equity is the value of a company's assets minus its liabilities. For Nasdaq's Capital Market, companies listed under the Equity Standard must keep at least $2.5 million in shareholders' equity. If equity falls below that, the company risks delisting.

A delisting notice is not an immediate removal. The company has the right to appeal to a Nasdaq Hearings Panel, which can grant additional time or uphold the delisting. If the appeal fails, the company's stock would be suspended and eventually delisted, moving to the over-the-counter (OTC) market.

This filing does not indicate any fraud or mismanagement; it reflects the financial challenge of maintaining minimum equity while posting net losses. The company's stock closed at $0.339 on August 21, down 1.74% from the previous close.

The next step is the appeal deadline of August 25, 2026. The company intends to request a hearing, but the outcome is uncertain.